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Background: Acute myeloid leukaemia (AML) with central nervous system (CNS) involvement in adults is
uncommon, and studies of this subject are scant.
Methods: We conducted a retrospective study to investigate the clinical aspects, cytogenetic abnormalities, molecular
gene mutations and outcomes of adult AML patients with CNS involvement. Three hundred and ninety-five patients
with newly diagnosed AML were reviewed.
Results: Twenty (5.1%) patients had CNS involvement, including 7 (1.8%) with initial CNS disease and 4 (1%) who
suffered an isolated CNS relapse. The patients with CNS involvement were younger, had higher leukocyte, platelet, and
peripheral blast cell counts, FAB M4 morphology, and chromosome translocations involving 11q23 (11q23 abnormalities)
more frequently than did the patients without CNS involvement. No differences in sex, haemoglobin levels, serum LDH
levels, immunophenotype of leukaemia cells, or molecular gene mutations were observed between the two groups.
Multivariate analyses showed that age≤ 45 years (OR, 5.933; 95% CI, 1.82 to 19.343), leukocyte counts≥ 50,000/μl (OR,
3.136; 95% CI, 1.083 to 9.078), and the presence of 11q23 abnormalities (OR, 5.548; 95% CI, 1.208 to 25.489) were
significant predictors of CNS involvement. Patients with initial CNS disease had 5-year overall survival and relapse-free
survival rates that were similar to those without initial CNS disease. However, three of four patients who suffered an
isolated CNS relapse died, and their prognosis was as poor as that of patients who suffered a bone marrow relapse.
Conclusion: CNS involvement in adult patients with AML is rare. Three significant risk factors for CNS involvement
including age≤ 45 years, leukocyte counts≥ 50,000/μl and the presence of 11q23 abnormalities were identified in this
study. Future investigations to determine whether adult AML patients having these specific risk factors would benefit
from CNS prophylactic therapy are necessary.
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Central nervous system (CNS) involvement in adults
with acute myeloid leukaemia (AML) is uncommon, and
its incidence is far less than that in patients with acute
lymphoblastic leukaemia [1,2]. Most descriptions of the
clinical features of AML with CNS involvement are from* Correspondence: hftien@ntu.edu.tw
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unless otherwise stated.studies of paediatric AML patients [3-6]. The incidence
of CNS involvement in childhood AML ranges from 6%
to 29% [5-9]. Previous studies have shown that age <
2 years, high white blood cell (WBC) and peripheral
blast cell (PBC) counts at diagnosis, French-American-
British (FAB) M4 and M5 morphology, inversion of
chromosome 16, and a hyperdiploid cytogenetic profile
are risk factors for CNS involvement in paediatric AML
patients at diagnosis [6-8]. On the other hand, isolated
CNS relapse in paediatric patients with AML is associated
with age < 2 years, high WBC count, hepatosplenomegaly,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chromosome 11q abnormalities [10]. Reports of the out-
comes of paediatric AML patients with CNS involvement
have varied. Certain studies have shown that CNS involve-
ment confers a poor prognosis, [11,12] whereas others
have shown that it exerts no effect on survival [5,7,8,10].
The clinical features and treatment outcomes of adult
AML patients with CNS involvement have not been well
characterised. Peterson et al [13] described adult patients
with acute nonlymphocytic leukaemia with CNS involve-
ment, but their sample size was relatively small.
Shihadeh et al [14] examined the cytogenetic profiles of
AML patients with CNS disease in a cohort of 1354 pa-
tients in the United States, but did not examine the clin-
ical outcomes. Rozovski et al [15] used the same cohort
as Shihadeh et al and found that high serum levels of lac-
tate dehydrogenase (LDH) at diagnosis, African-American
ethnicity, and young age were risk factors for CNS in-
volvement. Patients who achieved complete remission
(CR) after induction chemotherapy had shorter disease-
free survival and overall survival (OS) if they had CNS
involvement. Bar et al [16] reported risk factors and
outcomes for CNS AML involvement in patients at the
pre-haematopoietic stem cell transplantation (HSCT)
evaluation. Covariates associated with CNS involve-
ment were higher WBC counts at diagnosis, prior CNS
or other extramedullary disease, and disease status at
pre-HSCT evaluation. Presence of CNS involvement at
pre-HSCT evaluation had no impact on post-HSCT
outcome. However, participants in their study were lim-
ited to those who had undergone HSCT, which may
have confounded their findings. In this study, we inves-
tigated the clinical characteristics and outcomes of a
large cohort of adult AML patients in Taiwan to deter-
mine the risk factors and outcomes associated with CNS
involvement in AML. Several characteristics which had
not been included in previous studies, such as the immu-
nophenotype of leukaemia cells and 13 relevant molecular
gene mutations in AML, were also examined. In addition,
we investigated the impact of CNS involvement on out-
comes including separate analyses on those with initial
CNS disease and those with isolated CNS relapse.
Methods
Participants
Our study was approved by the Institutional Review
Board of National Taiwan University Hospital (NTUH),
and was performed in accordance with the Declaration
of Helsinki. All participants provided signed, informed
consent before participation in our study. Patients aged ≥
18 years who were newly diagnosed with AML at
NTUH between January 2000 and December 2008 were
reviewed for enrollment. The diagnosis and classification
of AML were made according to the criteria of the FABCooperative Group by the patient’s primary care haema-
tologist, an expert in FAB classification. Patients with
acute promyelocytic leukaemia (FAB M3 subtype), ante-
cedent haematological diseases or therapy-related AML
were excluded from our study.
A total of 395 AML patients were included in our
study, amongst whom 280 (70.9%) received standard in-
duction chemotherapy (idarubicin 12 mg/m2 per day for
three days and cytarabine 100 mg/m2 per day for seven
days) and then consolidation chemotherapy with three
to four courses of high-dose cytarabine (2000 mg/m2
every 12 hours for four days, total eight doses), with or
without an anthracycline (idarubicin or mitoxantrone),
after achieving CR [17]. The remaining 115 patients re-
ceived palliative therapy with supportive care and/or
low-dose chemotherapy because of underlying comor-
bidity or the patient’s request. Allogeneic HSCT was per-
formed in 97 patients. Our treatment protocols did not
routinely include CSF tested at diagnosis or CNS
prophylactic therapy, such as intrathecal chemotherapy.
Lumbar puncture was performed only if clinically indi-
cated. Intrathecal chemotherapy in combination with
systemic chemotherapy, including high dose cytarabine,
was adopted as the CNS-directed treatment for patients
with CNS involvement. Patients who failed to respond
completely to intrathecal or systemic chemotherapy, and
those who had CNS granulocytic sarcoma and/or cranial
nerve impairment, received radiation therapy. The me-
dian dose of radiation given to patients was 24 grays
(Gy) (range, 20 to 25 Gy).
Data collection
We retrospectively reviewed the clinical characteristics,
cytogenetic profiles, molecular gene mutations and out-
comes of patients in our AML cohort. A diagnosis of
CNS involvement required the confirmation of leu-
kaemic blast cells in the centrifuged cerebrospinal fluid
(CSF) with the presence of more than five WBCs in the
CSF [10,18] by at least two haematologists or the detec-
tion of a CNS granulocytic sarcoma using computed
tomography or magnetic resonance imaging. Two clin-
ical disease entities, initial CNS disease and isolated
CNS relapse, were defined. Initial CNS disease consisted
of the following conditions: (1) CNS involvement on the
date of the initial AML diagnosis or (2) CNS involve-
ment after receiving standard induction therapy and the
absence of blast cells in the peripheral blood. Isolated
CNS relapse was defined as a CNS relapse that was the
first event following CR without evidence of bone mar-
row (BM) or other extramedullary relapse within 30 days
[10]. The age, sex, FAB morphology subtype, haemo-
gram, PBC, serum LDH level, immunophenotype of leu-
kaemia cells, cytogenetics and molecular gene mutation
at diagnosis of patients with CNS involvement were
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ment. Follow-up data were collected until death, loss to
follow-up, or the end of the study period, June 30, 2011.
Immunophenotyping
Monoclonal antibodies to the myeloid-associated antigens
CD13, CD33, CD11b, CD15, and CD14, the lymphoid-
associated antigens CD2, CD5, CD7, CD19, CD10, and
CD20, and the lineage-nonspecific antigens HLA-DR,
CD34, and CD56 were used to characterise the immu-
nophenotype of the leukaemia cells as previously
described [19].
Cytogenetics
The BM cells were collected from AML patients for im-
mediate cytogenetic analysis, or they were cultured for 1
to 3 days without exogenous stimulation before cytogen-
etic analysis as described previously [20]. The metaphase
cells were banded using the trypsin-Giemsa technique,
and karyotyped according to the International System
for Human Cytogenetic Nomenclature (ISCN 2009) [21].
Mutation analysis
Mutation analysis of 13 relevant molecular marker
genes, including NPM1, [22] CEBPA, [23] FLT3-internal
tandem duplication, [24] RAS, [25] KIT, [26] MLL-partial
tandem duplication, [27] WT1, [28] AML1/RUNX1, [29]
ASXL1, [30] IDH1, [31] IDH2, [32] TET2, [33] and
DNMT3A [34] was performed as previously reported.
Abnormal sequencing results were confirmed by at least
two repeated analyses.
Statistical analysis
The categorical data for patients with CNS involvement
were compared with those of patients without CNS in-
volvement, using a chi-squared analysis or the Fisher
exact test. The Mann-Whitney U test was used to com-
pare the medians of the continuous variables. The uni-
variate and multivariate logistic regression analyses were
used to identify factors predictive of CNS involvement.
Variables that met a significance level of < 0.2 in the uni-
variate analysis were included in the multivariate logistic
regression analysis. The odds ratio (OR) from this ana-
lysis was used as a measure of the relative risk. OS was
measured from the date of the first diagnosis to the end
of the follow-up period, death from any cause, or the
date of the last known follow-up examination. Relapse
was defined as a reappearance of ≥ 5% leukaemic blast
cells in a BM aspirate or newly developed extramedul-
lary leukaemia in patients with a previously documented
CR [35]. Relapse-free survival (RFS) was measured from
the date of attaining a leukaemia-free state until the end
of the follow-up period, the date of AML relapse, death
from any cause, or the last known follow-up examination,whichever came first [35]. The Kaplan-Meier method was
used to estimate the OS and the RFS, and the log-rank test
was used to examine the significance of differences be-
tween the two groups. A two-sided P value < .05 was con-
sidered to indicate a statistically significant difference. The
entire cohort was included the analyses of the correlation
between CNS involvement and the clinical characteristics.
All patients with CNS involvement received standard in-
duction chemotherapy. Those in the palliative group re-
ceived heterogeneous treatment strategies. Hence only the
patients who received conventional standard chemother-
apy were included in the analysis of survival. All statistical
analyses were performed using the SPSS, Version 17, com-
puter software (IBM, Armonk, NY, USA).
Results
Characteristics of the patients
Of the 395 AML patients included in our study, 20
(5.1%) developed CNS involvement, amongst whom
seven (1.8%) had initial CNS disease and four (1%) suf-
fered an isolated CNS relapse. Six patients (1.5%) suf-
fered a CNS relapse concurrent with or subsequent to a
marrow relapse, and three patients (0.8%) were diag-
nosed with primary refractory disease with subsequent
CNS involvement. The clinical and laboratory data of
patients with or without CNS involvement are shown in
Table 1. Patients with CNS involvement had a lower me-
dian age (37.5 vs 54 y, P < .001), and exhibited higher
WBC, PBC, and platelet counts at diagnosis than those
of patients without CNS involvement. In addition, pa-
tients with CNS involvement exhibited FAB-M4-subtype
morphology more frequently (P = .02) than did patients
without CNS involvement. No differences in sex, haemo-
globin levels, serum LDH levels, or the immunopheno-
type of leukaemia cells (Additional file 1: Table S1) were
observed between the two groups.
Correlation of CNS involvement with cytogenetics and
molecular gene mutations
Cytogenetic data were available for 378 patients at diag-
nosis. The karyotype characteristics of the AML patients
are shown in Table 2. Patients with CNS involvement
had a significantly higher incidence of the chromosome
translocations involving 11q23 (11q23 abnormalities)
(21.1% vs 2.8%, P = .003) than did those without CNS in-
volvement. Data on molecular gene mutations of the
AML patients are shown in Additional file 1: Table S2.
The molecular gene mutations observed in the two
groups did not differ.
Risk factors associated with CNS involvement
In multivariate logistic regression analysis including vari-
ables significantly associated with CNS involvement in
univariate analysis (Table 3), the independent risk factors
Table 1 Comparison of clinical and laboratory characteristics of patients with and without CNS involvement
Variables Total (n = 395) Patients with CNS
involvement (n = 20)
Patients without CNS
involvement (n = 375)
P value
Sex† 0.648
Male 220 10(50) 210(56)
Female 175 10(50) 165(44)
Age (year)‡ 53(18-90) 37.5(21-72) 54(18-90) <0.001
Laboratory data‡
WBC (/μL) 21950(120-423000) 83865(1860-277250) 21050(120-423000) 0.003
Haemoglobin (g/dL) 8.1(2.9-14.5) 8.1(4.9-14.5) 8.1(2.9-14) 0.392
Platelet (×1,000 /μL) 45(1-802) 71.5(11-255) 44(1-802) 0.03
PBC (/μL) 9014(0-369070) 42751(0-260615) 8360(0-369070) 0.009
LDH (U/L) 859(206-13130) 1641.5(265-8693) 842(206-13130) 0.069
FAB†
M0 11 0(0) 11(2.9) >0.999
M1 85 4(20) 81(21.6) >0.999
M2 139 3(15) 136(36.3) 0.057
M4 116 11(55) 105(28) 0.02
M5 20 1(5) 19(5.1) >0.999
M6 15 0(0) 15(4) >0.999
Undetermined 9 1(5) 8(2.1) 0.377
†number of patients (%).
‡median (range).
Abbreviation: CNS central nervous system, WBC white blood cell, PBC peripheral blast cell, LDH lactate dehydrogenase, FAB French-American-British.
Table 2 Comparison of chromosomal abnormalities* seen in patients with and without CNS involvement
Variables Total (n = 378) Patients with CNS involvement (n = 19) Patients without CNS involvement (n = 359) P value
Number (%) of patients
Karyotype† 0.378
Favorable 50 3(15.8) 47(13.1)
Intermediate 264 15(78.9) 249(69.4)
Unfavorable 64 1(5.3) 63(17.5)
t(8;21) 34 1(5.3) 33(9.2) >0.999
inv(16) 16 2(10.5) 14(3.9) 0.189
11q23 abnormalities 14 4(21.1) 10(2.8) 0.003
-5/5q-‡ 1 0(0) 1(0.3) >0.999
-7/7q-‡ 6 0(0) 6(1.7) >0.999
t(7;11) 4 0(0) 4(1.1) >0.999
t(6;9) 2 0(0) 2(0.6) >0.999
+8‡ 17 1(5.3) 16(4.5) 0.592
*Three hundred and seventy-eight patients had cytogenetic profiles at diagnosis. The remaining 17 patients did not have data of cytogenetic profiles because of
inadequate metaphase cells for alalysis.
†Favorable, t(8;21), inv (16); unfavorable, -7, del(7q), -5, del(5q), 3q abnormality, complex abnormalities; Intermediate, normal karyotype and other abnormalities.
‡Includes only simple chromosomal abnormalities with 2 or fewer changes, but not those with complex abnormalities with 3 or more aberrations.
Abbreviation: CNS central nervous system.
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Table 3 Univariate and multivariate analyses to identify the risk factors predictive of CNS involvement
Variable Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Age* 5.654 2.01-15.904 0.001 5.933 1.82-19.343 0.003
Sex 0.786 0.319-1.932 0.599 - - -
WBC† 4.069 1.616-10.244 0.003 3.136 1.083-9.078 0.035
Platelet§ 2.303 0.755-7.026 0.143 2.804 0.799-9.837 0.107
LDH‡ 1.931 0.688-5.425 0.212 - - -
FAB M4¶ 3.143 1.266-7.803 0.014 2.023 0.646-6.341 0.227
inv(16) Δ 2.899 0.609-13.79 0.181 1.176 0.277-10.612 0.562
11q23 abnormalities# 9.307 2.615-33.123 0.001 5.548 1.208-25.489 0.028
Only variables with P value < 0.2 in the univariate analysis were incorporated into the multivariate logistic regression analysis.
*Age ≤ 45 y relative to age > 45 y.
†WBC greater than or equal to 50,000/μL vs less than 50,000/μL.
§Platelet greater than or equal to 30,000/μL vs less than 30,000/μL.
‡LDH greater than or equal to two times the upper limit of normal vs less than two times the upper limit of normal.
¶French-American-British M4 morphology vs others.
ΔInversion of chromosome 16 vs others.
#chromosome translocations involving 11q23 vs others.
Abbreviation: CNS, central nervous system; OR, odds ratio; CI, confidence interval; WBC, white blood cell; LDH, lactate dehydrogenase.
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WBC counts ≥ 50,000/μL (OR, 3.136; 95% CI, 1.083 to
9.078), and the presence of 11q23 abnormalities (OR,
5.548; 95% CI, 1.208 to 25.489).
Clinical characteristics and outcomes of patients with
initial CNS disease
The clinical features and treatment outcomes of the pa-
tients with initial CNS disease (n = 7) are summarized in
Table 4. Patients with initial CNS disease had higher
WBC counts at diagnosis (P = .041) than those without
initial CNS disease. Furthermore, the incidence of the
chromosome 16 inversion was significantly higher
(P = .001) in patients who had initial CNS disease than
in patients without initial CNS disease.
The CR rates and primary refractory rates amongst pa-
tients with initial CNS disease were similar to those of pa-
tients without initial CNS disease (Additional file 1: Table
S3). The median follow-up interval was 58.1 months
(range: 0.1-139.3). The 5-year OS and RFS rates of theTable 4 Clinical characteristics and treatment outcomes of pa
Patient Age (years) Gender FAB Leukocyte (/μL) Cyto
1 43 F M1 1860 CN
2 21 F M2 15430 t(8;21
3 60 F M4 74390 t(9;11
4 26 F M4 175900 inv(1
5 72 M M4 168630 inv(1
6 53 F M4 93340 +8
7 40 M M1 277250 CN
#This patient suffered from marrow relapse but not CNS relapse.
ΔThis patient suffered from induction death after standard induction chemotherapy
Abbreviation: F, female; M, male; FAB, French-American-British; CN, normal karyotyp
CR, complete remission; m, month.patients with initial CNS disease were not significantly dif-
ferent to those of the patients without initial CNS disease
(P = .252 and P = .123, respectively, Figure 1).
Clinical characteristics and outcomes of patients with
isolated CNS relapse
The clinical characteristics and treatment outcomes of
the four AML patients who suffered an isolated CNS re-
lapse are listed in Table 5. None of these patients had
initial CNS disease. The median interval from attaining
CR status to the first detection of isolated CNS relapse
was 3.2 months. The patients who suffered an isolated
CNS relapse were younger, had higher WBC counts and
were more likely to have FAB-M4-subtype morphology
than the patients without an isolated CNS relapse
(P = .008, P = .022, and P = 0.044, respectively). The
11q23 abnormalities were more prevalent amongst pa-
tients who suffered an isolated CNS relapse than in pa-
tients without CNS relapse (P < .001). Three of four
patients who suffered an isolated CNS relapse developed atients with initial CNS disease
genetics CNS Symptoms Relapse HSCT Outcome
Seizure Yes# Yes CR in 52.7 m
) Blurred vision No Yes CR in 41.4 m
)(p22;q23) Dizziness -Δ No Died in 3 m
6) Headache No No CR in 63.1 m
6) Dizziness No No CR in 40.9 m
Paresthesias No No Died in 4.3 m
Headache No No CR in 58.1 m
.
e; CNS, central nervous system; HSCT, hematopoietic, stem cell transplantation;
P=0.123
P=0.252
Patients with initial CNS 
disease (n=7)
Patients without initial CNS 
disease (n=273)
Patients without initial CNS 
disease (n=206)




Figure 1 Kaplan-Meier curves for overall survival (A) and relapse-free
survival (B) of AML patients ≥ 18 years of age stratified based their
status of CNS involvement at diagnosis. Only those receiving
conventional standard chemotherapy were included in the
survival analyses.
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an isolated CNS relapse was as poor as that following a
BM relapse, with a median interval from isolated CNS re-
lapse to death of 8.5 months (Figure 2).
Discussion
Our current study examined the rate of CNS involve-
ment in a large cohort of adult AML patients. The inci-
dence of CNS involvement amongst adult AML patients
at our institution was 5.1%. This result is similar to that
reported in other studies, that the incidence of CNS in-
volvement concurrent with or subsequent to AML diag-
nosis in adults is uncommon [1,15,36]. The AML
patients with CNS involvement were younger, exhibited
higher WBC, platelet, and peripheral blood blast cellcounts, and had FAB M4 morphology, and 11q23 abnor-
malities more frequently than did the AML patients
without CNS involvement. By multivariate analysis, the
risk factors significantly associated with CNS involve-
ment included age ≤ 45 years, WBC counts ≥ 50,000/μL,
and the presence of 11q23 abnormalities. No significant
difference in 5-year OS and RFS rates was observed be-
tween the AML patients with initial CNS disease and
those without it. In contrast, the prognosis of patients
who suffered an isolated CNS relapse was as poor as that
of patients who suffered a bone marrow relapse.
Young age has previously been considered as a risk
factor for CNS involvement and it was also observed in
this study [14,15,37]. Since certain FAB subtypes, such
as M4 AML, or cytogenetic abnormalities, such as the
chromosome 16 inversion, are commoner in younger
adults and are also more frequently associated with
extramedullary infiltrates, this is likely to at least partly
explain the association between CNS disease and youn-
ger age found in this and other studies. A large leu-
kaemic cell burden, as represented by high WBC counts
and high serum LDH levels, has been shown to be sig-
nificantly associated with CNS involvement [3,8,13-16].
We observed that AML patients with high WBC counts
at diagnosis had a significantly higher incidence of CNS
involvement (Table 3). However, the association between
serum LDH levels and CNS involvement was not statis-
tically significant in our study (P = 0.069).
Chromosomal changes or molecular gene mutations in
AML have clinical implications. Karyotype abnormalities,
such as the chromosome 16 inversion, chromosome
11q23 abnormality, trisomy 8, t(9;11) translocation, and
hyperdiploidism have been shown to be significantly asso-
ciated with CNS involvement in paediatric AML
[7,8,10,14]. We observed that the chromosome 16 inver-
sion was more prevalent amongst patients with initial
CNS disease, whereas the 11q23 abnormalities were more
common amongst patients that suffered an isolated CNS
relapse. These findings are consistent with those of previ-
ous studies of paediatric AML patients [8,10]. On the
other hand, no relevant molecular gene mutation associ-
ated with CNS involvement was identified in this study.
Reports of outcome about CNS involvement in adults
with AML are limited. Chang et al reported that extra-
medullary infiltrates were associated with poor outcome
in adult patients with AML, but their investigation did not
focus specifically on CNS involvement [38]. Mayadev et al
[39] showed that CNS involvement was associated with
poor prognosis in adult AML patients. On the contrary,
other two studies [16,37] showed that the outcomes for
AML with CNS involvement were comparable with those
for AML without CNS involvement. However, participant
selection for these three studies was limited to patients
who had undergone HSCT, which may have confounded


















1 24 M M5 113510 t(9;11;13)(p22;q23;q34) Nil Headache No Yes 2 - CR in 41.6 m
2 28 M M4 172700 t(11;19)(q23;p13) Nil Tremor Yes No 14 5.8 Died in 7.4 m
3 28 F M4 123550 t(6;11)(q27;q23) Nil Dizziness No Yes 3.3 14.9# Died in 41.4 m
4 35 M M4 33510 CN Nil Blurred vision Yes Yes 3.2 2.3 Died in 5.8 m
*All patients received intensive systemic chemotherapy and intrathecal chemotherapy.
#Bone marrow relapses of this patient happened after hematopoietic stem cell transplantation.













Patients with bone marrow 
relapse (n=110)
Patients with isolated CNS
relapse (n=4)
Figure 2 Kaplan-Meier curves for overall survival of AML patients≥
18 years of age with an isolated CNS relapse or a bone marrow relapse.
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tients with initial CNS disease were similar to those of
AML patients without CNS disease. These findings may
be partially explained by the higher frequency of favorable
cytogenetics (inversion of chromosome 16), the absence of
CNS relapse, and low rate of BM relapse (16.7%, Table 4)
amongst the patients with initial CNS disease. By contrast,
our data demonstrated that the outcome of patients who
suffered an isolated CNS relapse was actually poor. Three
of four patients (75%) who suffered an isolated CNS re-
lapse developed a subsequent BM relapse and died, des-
pite receiving cranial irradiation or allogeneic HSCT.
No consensus exists regarding the treatment of AML
patients with CNS involvement. The preference of treat-
ment protocols used in our study is largely based on the
capacity of intrathecal chemotherapy to clear the leu-
kaemic cells of CSF quickly in most patients and the effi-
cacy of high doses of cytarabine for penetrating the CNS
[40,41]. Moreover, the potential acute and long-term
complications associated with cranial irradiation often
limit its use. Aoki et al [37] reported that allogeneic
HSCT may improve outcomes for CNS involvement in
patients with AML. However, further prospective studies
are necessary to clarify this point. Future investigations
of more effective CNS-directed treatment strategies are
warranted to improve the outcomes of such patients,
particularly those who suffer an isolated CNS relapse.
The limitation of our study is that this is a single
centre, retrospective study. Nevertheless, most published
studies concerning this subject have also been retro-
spective. Identifying adult patients with AML who are at
risk for CNS involvement will enable us to restrict the
use of CNS prophylactic therapy to those who are most
likely to benefit. In this study three significant risk fac-
tors for CNS involvement in adult patients with AMLwere recognized. Further studies with large cohorts are
necessary to validate this point.
Conclusions
Our study of a large cohort of adult AML patients re-
vealed that the incidence of CNS involvement is low.
Age ≤ 45 years, WBC counts ≥ 50,000/μL and the pres-
ence of 11q23 abnormalities are independent risk factors
for adult AML patients with CNS involvement either at
diagnosis or during the course of the disease. The OS
rate is similar between patients with initial CNS disease
and those without it. However, the prognosis of patients
who suffer an isolated CNS relapse is as poor as that of
patients who suffered a bone marrow relapse. Whether
routine CNS prophylactic therapy should be given as
part of conventional standard chemotherapy in adult
AML patients having these specific risk factors needs to
be further investigated.
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